29554190|t|A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
29554190|a|Importance: Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD copathology. Objective: To develop an algorithm based on core AD CSF measures to exclude cases with AD pathology and then differentiate between FTLD-tau and FTLD transactive response DNA-binding protein of approximately 43kDa (FTLD-TDP). Design, Setting, and Participants: A case-control study at the University of Pennsylvania. Participants were selected from a database of 1796 patients included between 1992 and 2016 with different neurodegenerative diseases with available CSF. Three patient cohorts were included: a cohort of patients with sporadic, autopsy-confirmed FTLD and AD (n = 143); a cohort of patients with frontotemporal degeneration (FTD) with TDP-associated or tau-associated mutations (n = 60); and a living cohort of patients with syndromes highly predictive of FTLD (progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis; n = 62). Main Outcomes and Measures: Cerebrospinal fluid values of amyloid beta1-42 (Abeta1-42), total tau (t-tau), and p-tau obtained using the INNO-BIA AlzBio3 (xMAP; Luminex) assay or INNOTEST enzyme-linked immunosorbent assay transformed using a previously validated algorithm. Sensitivities and specificities for differentiating AD from FTLD groups were calculated. Results: This autopsy cohort included FTLD-tau (n = 27; mean [SD] age at onset, 60.8 [9.7] years), FTLD-TDP (n = 13; mean [SD] age at onset, 62.4 [8.5] years), AD (n = 89, mean [SD] age at onset, 66.5 [9.7] years); and mixed FTLD-AD (n = 14, mean [SD] age at onset, 70.6 [8.5] years).The p-tau/Abeta1-42 ratio showed an excellent diagnostic accuracy to exclude AD cases in the autopsy cohort with single neurodegenerative pathologies (area under the curve [AUC], 0.98; 95% CI, 0.96-1.00). Cerebrospinal fluid p-tau levels showed a good AUC (0.87; 95% CI, 0.73-1.00) for discriminating pure FTLD-TDP from pure FTLD-tau. The application of an algorithm using cutpoints of CSF p-tau to Abeta1-42 ratio and p-tau allowed a good discrimination of pure FTLD-TDP cases from the remaining FTLD-tau and mixed FTLD cases. The diagnostic value of this algorithm was confirmed in an independent cohort of living patients with progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis (AUC, 0.9; 95% CI, 0.81-0.99). However, the algorithm was less useful in FTD cases carrying a pathogenic mutation (AUC, 0.58; 95% CI, 0.38-0.77) owing to elevated p-tau levels in TDP-associated mutation carriers. Conclusions and Relevance: Alzheimer disease CSF core biomarkers can be used with high specificity for the in vivo identification of patients with pure FTLD-TDP and FTLD-tau when accounting for comorbid AD and genetic status.
29554190	54	87	Frontotemporal Lobar Degeneration	Disease	MESH:D057174
29554190	141	158	Alzheimer disease	Disease	MESH:D000544
29554190	160	162	AD	Disease	MESH:D000544
29554190	237	239	AD	Disease	MESH:D000544
29554190	303	306	tau	Gene	4137
29554190	335	338	tau	Gene	4137
29554190	352	385	frontotemporal lobar degeneration	Disease	MESH:D057174
29554190	387	391	FTLD	Disease	MESH:D057174
29554190	414	416	AD	Disease	MESH:D000544
29554190	479	481	AD	Disease	MESH:D000544
29554190	517	519	AD	Disease	MESH:D000544
29554190	561	569	FTLD-tau	Disease	MESH:D057174
29554190	574	578	FTLD	Disease	MESH:D057174
29554190	644	648	FTLD	Disease	MESH:D057174
29554190	649	652	TDP	Disease	MESH:D016171
29554190	797	805	patients	Species	9606
29554190	852	878	neurodegenerative diseases	Disease	MESH:D019636
29554190	905	912	patient	Species	9606
29554190	948	956	patients	Species	9606
29554190	990	994	FTLD	Disease	MESH:D057174
29554190	999	1001	AD	Disease	MESH:D000544
29554190	1025	1033	patients	Species	9606
29554190	1039	1066	frontotemporal degeneration	Disease	MESH:D057174
29554190	1068	1071	FTD	Disease	MESH:D057174
29554190	1078	1081	TDP	Disease	MESH:D016171
29554190	1096	1099	tau	Gene	4137
29554190	1154	1162	patients	Species	9606
29554190	1199	1203	FTLD	Disease	MESH:D057174
29554190	1205	1235	progressive supranuclear palsy	Disease	MESH:D013494
29554190	1240	1243	FTD	Disease	MESH:D057174
29554190	1244	1273	amyotrophic lateral sclerosis	Disease	MESH:D000690
29554190	1378	1381	tau	Gene	4137
29554190	1385	1388	tau	Gene	4137
29554190	1609	1611	AD	Disease	MESH:D000544
29554190	1617	1621	FTLD	Disease	MESH:D057174
29554190	1684	1692	FTLD-tau	Disease	MESH:D057174
29554190	1745	1749	FTLD	Disease	MESH:D057174
29554190	1750	1753	TDP	Disease	MESH:D016171
29554190	1806	1808	AD	Disease	MESH:D000544
29554190	1871	1875	FTLD	Disease	MESH:D057174
29554190	1876	1878	AD	Disease	MESH:D000544
29554190	2007	2009	AD	Disease	MESH:D000544
29554190	2050	2079	neurodegenerative pathologies	Disease	MESH:D019636
29554190	2236	2240	FTLD	Disease	MESH:D057174
29554190	2241	2244	TDP	Disease	MESH:D016171
29554190	2255	2263	FTLD-tau	Disease	MESH:D057174
29554190	2393	2397	FTLD	Disease	MESH:D057174
29554190	2398	2401	TDP	Disease	MESH:D016171
29554190	2427	2435	FTLD-tau	Disease	MESH:D057174
29554190	2446	2450	FTLD	Disease	MESH:D057174
29554190	2546	2554	patients	Species	9606
29554190	2560	2590	progressive supranuclear palsy	Disease	MESH:D013494
29554190	2595	2598	FTD	Disease	MESH:D057174
29554190	2599	2628	amyotrophic lateral sclerosis	Disease	MESH:D000690
29554190	2702	2705	FTD	Disease	MESH:D057174
29554190	2808	2811	TDP	Disease	MESH:D016171
29554190	2869	2886	Alzheimer disease	Disease	MESH:D000544
29554190	2975	2983	patients	Species	9606
29554190	2994	2998	FTLD	Disease	MESH:D057174
29554190	2999	3002	TDP	Disease	MESH:D016171
29554190	3007	3015	FTLD-tau	Disease	MESH:D057174
29554190	3045	3047	AD	Disease	MESH:D000544
29554190	Association	MESH:D057174	4137
29554190	Association	MESH:D016171	4137

